Results 141 to 150 of about 67,182 (253)

Examining the potential of mobile money-based health insurance for people living with HIV and hypertension or diabetes in Uganda. [PDF]

Front Health Serv
Zakumumpa H, Ssempala R, Kiplagat J, Kwiringira J, Quentin W, Struckmann V.   +5 more
europepmc   +1 more source

A sustainable business ecosystem: a case study demonstrating biochar's potential

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract The need for renewable, climate‐friendly resources has become urgent as legislators worldwide have sought to find ways to cut emissions while ensuring resource security for consumers. The use of biochar could help to achieve these goals. This study examines the current state of commercial biochar production and the maturity of the related ...
Juuso Kivijakola, Eemeli Erkheikki, Viljo Lukka, Pekka Tervonen, Harri Haapasalo   +4 more
wiley   +1 more source

Analyzing the Effectiveness of Macroeconomic Policies in Addressing Poverty in Iraq: An Econometric Study considering Digital Transformation and Artificial Intelligence for the Period (2004-2024). [PDF]

F1000Res
Abdullah Abid Al Mihimdy N, Saleh Attia AA, Ministry of Finance–General Tax Authority.   +2 more
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Reusing Haemodialysis Reverse Osmosis Reject Water: A Case Report From a Sydney Metropolitan Hospital, Australia. [PDF]

Can J Kidney Health Dis
Hsu WY, Huang B, Lees S, Veros H, Smyth B, Mangos G, Gallagher A.   +6 more
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

What is the Value of Developing an HTA Process? [PDF]

Pharmacoeconomics
Murphy P, Walker S, Putri S, Sculpher M, Griffin S.   +4 more
europepmc   +1 more source

Illegal markets for cigarettes and e-cigarettes. [PDF]

Proc Natl Acad Sci U S A
Kenkel D, Phillips G.
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source